James Talano, MD
Cardiovascular Disease · Naples, FLNPI 1881620540
Payments from drug & device makers
Across 190 payments — averaging $1202.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$107K
- Boehringer Ingelheim International GmbH$30K
- Esperion Therapeutics, Inc.$24K
- Bayer$22K
- AstraZeneca$22K
- Boehringer Ingelheim Pharma GmbH & Co.kg$8K
- plus $15K from 20 others
What the payments were for
- Travel & lodging$2869%
- Food & beverage$3,01591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 20 | $107,007 |
| Boehringer Ingelheim International GmbH | 38 | $30,039 |
| Esperion Therapeutics, Inc. | 35 | $24,446 |
| Bayer | 21 | $22,477 |
| AstraZeneca | 6 | $21,656 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 1 | $8,133 |
| Novartis | 15 | $7,289 |
| Merck | 5 | $5,272 |
| Abbott | 6 | $622 |
| Johnson & Johnson | 15 | $236 |
| Impulse Dynamics (USA) Inc. | 2 | $210 |
| Edwards Lifesciences | 1 | $173 |
| Medtronic | 1 | $125 |
| Alnylam Pharmaceuticals Inc. | 2 | $122 |
| Akcea Therapeutics, Inc. | 1 | $122 |
| Kestra Medical Technology Services, Inc. | 1 | $118 |
| Novo Nordisk | 4 | $90 |
| Cvrx, Inc. | 1 | $68 |
| Pfizer | 4 | $66 |
| Scpharmaceuticals Inc. | 2 | $46 |
| Arthrex | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $29 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Mitra Clip system$444
- OPTIMIZER$360
- MitraClip System$142
- Micra$125
- TEGSEDI$122
- INVOKANA$121
- Assure WCD$118
How this compares
$228,477 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 182 | $251,588 |
| Repatha SureclickEvolocumab | 93 | $135,095 |
| EntrestoSacubitril/Valsartan | 60 | $97,630 |
| XareltoRivaroxaban | 51 | $61,257 |
| JardianceEmpagliflozin | 40 | $55,562 |
| MounjaroTirzepatide | 36 | $45,454 |
| Praluent PenAlirocumab | 26 | $34,184 |
| JanuviaSitagliptin Phosphate | 22 | $21,566 |
| OzempicSemaglutide | 14 | $20,195 |
| NexlizetBempedoic Acid/Ezetimibe | 15 | $12,823 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $9,166 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $8,097 |
| InvokanaCanagliflozin | 12 | $7,228 |
| Metoprolol Succinate | 294 | $6,151 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 11 | $5,256 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $66 | $254,216193 claims |
| NovartisEntresto | $7,289 | $97,63060 claims |
| Johnson & JohnsonXarelto, Invokana | $236 | $68,48563 claims |
| Boehringer IngelheimJardiance | $18 | $55,56240 claims |
| Lilly USA, LLCMounjaro | $20 | $45,45436 claims |
| MerckJanuvia, Janumet Xr | $5,272 | $30,73236 claims |
| Novo NordiskOzempic | $90 | $20,19514 claims |
| Esperion Therapeutics, Inc.Nexlizet | $24,446 | $12,82315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Naples
- William OneillNaples$4.6M
- Ronald CaputoNaples$1.4M
- Michael KorenGainesville$31M
- Seth BaumBoca Raton$11.1M
- Alexis GutierrezHialeah$8M
- Eric SpivackAventura$7.1M
- Rafik AbadierInverness$4.4M
- Alvaro MurciaPembroke Pines$4M
- David HotchkissPort Charlotte$4M
- Ferris GeorgeSt Augustine$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.